Canada Pension Plan Investment Board
TRDA icon

Canada Pension Plan Investment Board’s Entrada Therapeutics TRDA Stock Holding History

Canada Pension Plan Investment Board’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-17,700
Closed -$223K – 1870
2026
Q1 		$223K Sell
17,700
-7,900
-31% -$90.5K ﹤0.01% 1538
2025
Q4 		$263K Buy
+25,600
New +$216K ﹤0.01% 1562

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Canada Pension Plan Investment Board's TRDA Position: Q2 2026 in Review

Canada Pension Plan Investment Board sold out of Entrada Therapeutics (TRDA) in Q2 2026, closing a stake of 17,700 shares — an estimated $223K sold.

Canada Pension Plan Investment Board first reported a position in TRDA in Q4 2025 and held it in 2 quarters. The position peaked at $263K in Q4 2025. 128 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Canada Pension Plan Investment Board reported no remaining Entrada Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Canada Pension Plan Investment Board sold 17,700 Entrada Therapeutics shares in Q2 2026, an estimated $223K.
  • Canada Pension Plan Investment Board first reported a position in Entrada Therapeutics in Q4 2025 and held it in 2 quarters.
  • Canada Pension Plan Investment Board's Entrada Therapeutics position peaked at $263K in Q4 2025.
  • 128 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Canada Pension Plan Investment Board's 13F filing for Q2 2026, filed 14 Aug 2026.